Psyence Biomed, a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, agreed to go public via a SPAC merger with Newcourt Acquisition, a special purpose acquisition company, in a $50m deal. "This merger represents a pivotal moment for Psyence as we continue our journey to redefine health and wellness. The NASDAQ listing, as well as the capital infusion, expands our presence to additional investors in North America and will empower us to accelerate our clinical trials and contribute to advancements in the global health and wellness landscape," Dr. Neil Maresky, Psyence Biomed CEO.